Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 08/26 05:35:06 pm
73.28 EUR   +1.74%
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimp..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UCB : marks World Parkinson’s Disease Day with new ‘Parkinson’s Well-Being Map™’

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 07:34am CEST

• The Parkinson's Well-Being Map™ is a new visual tool to support communication of a person's Parkinson's status with their healthcare team
• 'Living with Parkinson's Disease: Insights and Inspirations' video shares personal and motivational perspectives on PD

Brussels, Belgium, 11th April 2012, 0700 CET - UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map™ is a visual tool designed to help people with PD discuss their health status and well-being with their care teams. A new video 'Living with Parkinson's Disease: Insights and Inspirations' is also shared today and gives a voice to people with Parkinson's on the effects of the condition on their lives.

The Parkinson's Well-Being Map™ was developed by UCB in consultation with people living with PD and in partnership with the European Parkinson's Disease Association (EPDA), the Cure Parkinson's Trust and the Spanish Federation of Parkinson's Disease.

"The Parkinson's Well-Being Map™ translates a complex issue into an 'at-a-glance' summary of symptoms of an individual's Parkinson's. By including both movement related and underlying symptoms, it can help people talk to their healthcare team about all aspects of Parkinson's including symptoms such as sleep disturbances and mood changes, which they may not have realised could be part of their Parkinson's," said Knut-Johan Onarheim, President of the EPDA.

Designed to be simple and easy to use, the Parkinson's Well-Being Map™ should help people with Parkinson's monitor and record their symptoms over time as well as summarise their health and well-being in preparation for their consultation with their healthcare team. The Map is already available in paper format in certain countries worldwide, and will be available in further countries during 2012.

UCB is committed to supporting educational programs that inspire and encourage people living with Parkinson's Disease to achieve their personal goals and to support communication on their health and well-being with their care team. The Parkinson's Well-Being Map™ builds on 'Today I will…' an ongoing initiative from UCB which encourages people affected by Parkinson's to make motivational pledges to inspire and support others.

'Today I will…' pledges received to date include:

• "Today I will… take inspiration from other pledges, then hopefully realise I'm not alone. I thank you all."
• "Today I will… totally forget my Parkinson's when walking in the sun, the energy comes back, the winter time is over and then I really enjoy my life!"
• "Today I will… ask my patient how they are living rather than how they are moving."

"Parkinson's Disease is a complicated condition which can have a significant impact on how people live their lives. At UCB we are committed to supporting people with Parkinson's by developing resources that help them to communicate their full range of symptoms to their healthcare teams and connect with each other for motivation and inspiration," said Lode Dewulf, MD, Vice President, Global Medical Affairs, UCB.

People can show their support on World Parkinson's Disease Day by viewing 'Living with Parkinson's Disease: Insights and Inspirations' at http://www.youtube.com/user/UCB?ob=0&feature=results_main or to learn more about UCB's educational initiatives to inspire people with Parkinson's including the Parkinson's Well-Being Map™ and 'Today I will…' visit www.parkinsons-voices.eu.

For further information
Eimear O Brien, Director, Communications, UCB
T +32.2.559.9271, eimear.obrien@ucb.com

NOTES TO EDITORS

About World Parkinson's Disease Day
World Parkinson's Disease Day is marked on April 11 in commemoration of the birth of Dr. James Parkinson (1755 - 1824) who established the disease as a clinical entity.1 Activities on this day aim to raise public awareness for one of the most common progressive degenerative neurological disorders and to show support for people living with the condition.

About Parkinson's Voices ( )
Parkinson's Voices (www.parkinsons-voices.eu) is a UCB website created for people who want to know more about PD, to share experiences with those who have the condition, and to find out how different members of their healthcare team can help them. www.parkinsons-voices.eu

About Parkinson's Disease
PD is a progressive neurological condition which affects over six million people worldwide.2 It is predominantly characterised by problems with body movements, known as 'motor symotoms'.2 The classical symptoms of PD are tremor, muscular rigidity and bradykinesia including slowness and poverty of movement.3 Other underlying symptoms that are not related to movement can also occur such as pain, sleep disturbance and mood changes.2

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

References
1. European Parkinson's Disease Association Charter. 1997. Available at http://www.epda.eu.com/worldpdday/epda-charter/ Last accessed March 2012
2. European Parkinson's Disease Association - Life with Parkinson's disease: What is Parkinson's disease? Available at: http://www.parkinsonsawareness.eu.com/en/campaign-literature/what-is-parkinsons-disease/ Last accessed March 2012
3. European Parkinson's Disease Association - Life with Parkinson's disease: Symptoms Available at: http://www.parkinsonsawareness.eu. Last accessed March 2012

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
08/05 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
07/28 UCB : continues to deliver on its growth strategy
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
06/08 UCB : commitment to addressing real world patient needs on display at the Annual..
More news
Sector news : Pharmaceuticals - NEC
12:53a Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/31 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
07/31 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2016 Results - Earnings Call ..
07/22 Amgen submits BLA in U.S. for osteoporosis candidate romosozumab
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
Advertisement
Financials (€)
Sales 2016 4 047 M
EBIT 2016 736 M
Net income 2016 465 M
Debt 2016 988 M
Yield 2016 1,73%
P/E ratio 2016 28,48
P/E ratio 2017 23,01
EV / Sales 2016 3,77x
EV / Sales 2017 3,47x
Capitalization 14 253 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 78,8 €
Spread / Average Target 7,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB-11.95%15 957
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results